Robert Pirker Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncology, Milan Pat Price, Christie Hospital, Manchester Gianni Bonadonna, I
Robert Pirker
Scientific Editors:George Canellos, Dana-Farber Cancer Institute, BostonGordon McVie, European Institute of Oncology, MilanPat Price, Christie Hospital, ManchesterGianni Bonadonna, Istituto Nazionale Tumori, Milan
Sarah Maxwell and Peter Goodwin report on evidence that combining monoclonal antibodies with chemotherapy can extend life among patients with advanced non-small-cell lung cancer.Robert Pirkerfrom the Medical University of Vienna tells Sarah Maxwell about his group’s findings in the FLEX study using the epidermal growth factor receptor (EGF-R) inhibitor cetuximab;Christian Manegoldfrom Heidelberg University, Manheim gives Peter Goodwin data on the vascular endothelial growth factor (VEGF-R) bevacizumab; whileGiorgio Scagliottifrom Torino University,Nick Thatcherfrom the Christie Hospital, Manchester andHoward Sandlerfrom the University of Michigan, Ann Arbor discuss the clinical implications of these approaches to using molecular targeting to improve outcomes in advanced non-small-cell lung cancer.Michel Colemanfrom the London School of Hygiene and Tropical Medicine tells Peter Goodwin about the findings of the CONCORD study looking at international differences between survival rates for breast, prostate and colorectal cancers.
Christian Manegold
Giorgio Scagliotti
Nick Thatcher
Michel Coleman